Role of sentinel lymph node biopsy for oral squamous cell carcinoma: Current evidence and future challenges.
Sophie S JangMorgan E DavisDavid R VeraStephen Y LaiTheresa W GuoPublished in: Head & neck (2022)
Sentinel lymph node biopsy (SLNB) has been used across oncological specialties for prognostication, staging, and identification of occult nodal metastasis. Recent studies demonstrated the potential clinical utility of SLNB in oral cavity squamous cell carcinoma (OCSCC). Elective neck dissection is the current standard of care in early management of OCSCC with depth of invasion greater than 2-4 mm; however, majority of patients ultimately do not have nodal disease on final pathology. SLNB is an alternative procedure widely adopted in early cancer management in many oncological subspecialities. Several considerations such as depth of invasion, nodal mapping, histopathology methods, operator variability, postoperative complications, and advancement in preoperative and intraoperative imaging technology can guide the appropriate application to SLNB in OCSCC. The aim of this review is to discuss the current evidence for SLNB in the treatment of early stage OCSCC, imaging technologies that support SLNB procedures, and studies that are currently underway.
Keyphrases
- chronic kidney disease
- sentinel lymph node
- end stage renal disease
- lymph node
- neoadjuvant chemotherapy
- early stage
- high resolution
- squamous cell carcinoma
- locally advanced
- patients undergoing
- rectal cancer
- healthcare
- cell migration
- radical prostatectomy
- prostate cancer
- ultrasound guided
- optical coherence tomography
- prognostic factors
- newly diagnosed
- robot assisted
- ejection fraction
- quality improvement
- mass spectrometry
- photodynamic therapy
- current status
- peritoneal dialysis
- risk assessment
- young adults
- pet ct
- health insurance
- fine needle aspiration
- human health
- squamous cell
- chronic pain
- pain management
- affordable care act